Suchergebnisse - "Warren, R.B."

PubPharm (250)

1

Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis : a multinational cohort study

enthalten in: BMJ open | 2023

von Phan, D. | Jourdain, H. | González-Quesada, A. | +9

2

Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis : a post hoc pooled analysis of AMAGINE-2 and -3

enthalten in: Journal of the European Academy of Dermatology and Venereology : JEADV | 2022

von Reich, K. | Iversen, L. | Puig, L. | +4

3

Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment : a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis

enthalten in: Journal of the European Academy of Dermatology and Venereology : JEADV | 2022

von Gooderham, M. | Pinter, A. | Ferris, L. | +8

4

Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey

enthalten in: bioRxiv.org | 2022

von Bechman, K. | Cook, E. | Dand, N. | +36

5

Anakinra for palmoplantar pustulosis : results from a randomized, double‐blind, multicentre, two‐staged, adaptive placebo‐controlled trial (APRICOT)*

enthalten in: British Journal of Dermatology | 2022

von Cro, S. | Cornelius, V. | Pink, A. | +35

6

Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment : a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis

enthalten in: Journal of the European Academy of Dermatology and Venereology | 2022

von Gooderham, M. | Pinter, A. | Ferris, L. | +8

7

Long‐term efficacy and safety of brodalumab in moderate‐to‐severe plaque psoriasis : a post hoc pooled analysis of AMAGINE‐2 and ‐3

enthalten in: Journal of the European Academy of Dermatology and Venereology | 2022

von Reich, K. | Iversen, L. | Puig, L. | +4

8

Secukinumab improves the quality‐of‐life of family members and partners of people with psoriasis : Family Dermatology Life Quality Index (FDLQI) results from a randomised open‐label study (SIGNATURE)

enthalten in: JEADV Clinical Practice | 2022

von Finlay, A. | Barker, J. | Burden, A. | +5

9

Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis : results from the randomized phase 3 CIMPACT trial

enthalten in: Journal of the European Academy of Dermatology and Venereology : JEADV | 2021

von Warren, R. | Lebwohl, M. | Sofen, H. | +6

10

Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3

enthalten in: Journal of the European Academy of Dermatology and Venereology : JEADV | 2021

von Reich, K. | Hansen, J. | Puig, L. | +2

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[25]